DaVita (DVA)
(Delayed Data from NYSE)
$161.97 USD
+1.87 (1.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $161.95 -0.02 (-0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$161.97 USD
+1.87 (1.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $161.95 -0.02 (-0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth D Momentum A VGM
Zacks News
3 Top-Rated Stocks to Buy After Comfortably Surpassing Earnings Expectations
by Shaun Pruitt
Investors are always looking for stocks of companies that illustrate business operations are stronger than anticipated and here are three to consider.
4 Stocks to Watch in a Resilient Outpatient Home Health Industry
by Debanjana Dey
The rising dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry despite the macroeconomic challenges. DVA, EHC, OPCH and ADUS are well-poised to gain.
DaVita Inc. (DVA) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
DaVita HealthCare (DVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
DaVita (DVA) Q4 Earnings & Revenues Top Estimates, Margins Up
by Zacks Equity Research
DaVita's (DVA) robust segmental revenues drive its fourth-quarter performance.
DaVita HealthCare (DVA) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
DaVita HealthCare (DVA) delivered earnings and revenue surprises of 22.22% and 4.82%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
ResMed (RMD) to Treat Sleep Apnea With New AirCurve 11 Device
by Zacks Equity Research
ResMed's (RMD) new AirCurve11 series incorporates myAir and AirView digital health apps to provide maximum comfort and support during therapy.
Here's Why You Should Retain Charles River (CRL) Stock Now
by Zacks Equity Research
Charles River's (CRL) share price is likely to grow, backed by the strength of the RMS segment.
Quest Diagnostics (DGX) Debuts PFAS Blood Test Offering
by Zacks Equity Research
Quest Diagnostics (DGX) introduces the first consumer-initiated blood test with physician consult on questhealth.com.
Time to Buy These High Growth Stocks as Earnings Approach
by Shaun Pruitt
This week's earnings lineup will be highlighted by several growth stocks with none standing out more than Airbnb (ABNB) and DaVita (DVA).
Here's Why You Should Add HealthEquity (HQY) to Your Portfolio
by Zacks Equity Research
HealthEquity's (HQY) strength in HSA raises optimism about the stock.
Medical Device Stocks' Earnings Due on Feb 13: ECL, DVA & QDEL
by Indrajit Bandyopadhyay
Medical Device companies' quarterly results are likely to reflect a year-over-year decline in earnings. Let's see how ECL, DVA and QDEL fare this time.
DaVita (DVA) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Improvement in revenue per treatment and cost-saving initiatives are likely to have boosted DaVita's (DVA) top line in the fourth quarter.
Here's Why You Should Invest in Boston Scientific (BSX) Now
by Zacks Equity Research
Investors are optimistic about Boston Scientific (BSX) on strength across the target market and upbeat guidance.
IDEXX's (IDXX) Global Growth Continues, Currency Woes Persist
by Zacks Equity Research
A key element of IDEXX's (IDXX) customer engagement strategy is the expansion of its commercial footprint in a disciplined approach.
Insulet's (PODD) Omnipod 5 Gets CE Mark for Added Compatibility
by Zacks Equity Research
Insulet's (PODD) tubeless automated insulin delivery system's CE mark approval with multiple CGM sensor brands is likely to serve a wider patient pool.
Is Ardelyx (ARDX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Ardelyx (ARDX) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.
Hologic (HOLX) Introduces Genius Digital Diagnostics System
by Zacks Equity Research
Hologic's (HOLX) Genius Digital Diagnostics System will assist laboratories and healthcare providers with the information needed to make more timely and successful treatment decisions for patients.
Three Reasons to Retain BD (BDX) Stock in Your Portfolio
by Zacks Equity Research
BD's (BDX) slew of product launches raises optimism about the stock.
Edwards Lifesciences (EW) Wins FDA Nod for the EVOQUE System
by Zacks Equity Research
Edwards Lifesciences' (EW) EVOQUE valve replacement system becomes the first transcatheter therapy to earn FDA approval for a tricuspid valve.
Reasons to Retain Quest Diagnostics (DGX) Stock for Now
by Zacks Equity Research
Strength of the base business bodes well for Quest Diagnostics (DGX).
Modular Medical (MODD) Pairing Technology Issued New U.S. Patent
by Zacks Equity Research
Modular Medical's (MODD) latest U.S. patent is likely to protect the company's technology addressing pairing and allow clinicians to easily upload and review patients' data.
Boston Scientific's (BSX) FARAPULSE PFA System Gets FDA Nod
by Zacks Equity Research
Boston Scientific (BSX) secures FDA approval for the FARAPULSE PFA system.
Trinity Biotech (TRIB) to Grow in Wearable Biosensor With Buyout
by Zacks Equity Research
Trinity Biotech's (TRIB) focus on CGM as an initial step, utilizing a device with regulatory approval, provides a de-risked entry point in the wearable biosensor technology space.
Insulet (PODD) Gains From Product Innovation, Global Expansion
by Zacks Equity Research
Insulet's (PODD) Omnipod 5 continues to be a driving force behind U.S. and international growth.
The Zacks Analyst Blog Highlights Arista Networks, Chipotle Mexican Grill, Netflix, DaVita and Royal Caribbean Cruises
by Zacks Equity Research
Arista Networks, Chipotle Mexican Grill, Netflix, DaVita and Royal Caribbean Cruises are part of the Zacks top Analyst Blog.